Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges by Man Wang, Fei Yu, Yuan Zhang

“…Strategies to remove these hindrances mainly focus on the development of combinatorial therapies or the exploitation of novel immunotherapeutic mediations. Nanomaterials carrying anticancer agents to the target site are considered as practical approaches for cancer treatment. …”
Get full text

The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy by Abdo Meyiah, Faez Iqbal Khan, Dia Aldeen Alfaki, Khaled Murshed, Afsheen Raza, Eyad Elkord

“…These include identifying targets for cancer therapies, targeting molecular signaling, and enhancing the efficacy of immunotherapeutic modalities. Furthermore, targeting stromal and angiogenic factors in the TME may provide new therapeutic options. …”
Get full text

Defects of CTLA-4 Are Associated with Regulatory T Cells in Myasthenia Gravis Implicated by Intravenous Immunoglobulin Therapy by Wenhua Xu, Mingshan Ren, Swagata Ghosh, Kai Qian, Zhaofeng Luo, Aimei Zhang, Cuiping Zhang, Jiajun Cui

“…Intravenous immunoglobulin (IVIg) is an expensive and commonly used immunotherapeutic approach to treat patients with MG. The mechanisms of actions involved in IVIg treatment, however, remain to be investigated. …”
Get full text

Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer by Liying Sun, Chao Liu, Junping Peng

“…Background: The Epstein-Barr virus (EBV) is intricately linked to a range of human malignancies, with EBV latent membrane protein 2A (LMP2A) emerging as a potential target antigen for immunotherapeutic strategies in the treatment of nasopharyngeal carcinoma (NPC). …”
Get full text

Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients by Zhaoyue Yan, Yushuai Gao, Jinliang Yu, Zhiyuan Shen, Xingyao Bu

“…The differences in clinical correlations, immune infiltrate types, immunotherapeutic response predictions, and pathway enrichment among subgroups were investigated via bioinformatic algorithms. …”
Get full text

Integrative analysis of Ewing’s sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy by Fangzhou He, Jiuhui Xu, Fanwei Zeng, Boyang Wang, Yi Yang, Jie Xu, Xin Sun, Tingting Ren, Xiaodong Tang

“…Methods Since novel immunotherapies may address this need, we performed an integrative analysis involving single-cell RNA sequencing, cell function experiments, and humanized models to dissect the immunoregulatory interactions in EwS and identify strategies for optimizing immunotherapeutic efficacy. Results EwS is infiltrated by immunosuppressive myeloid populations, T and B lymphocytes, and natural killer cells. …”
Get full text

IL1RN and PRRX1 as a Prognostic Biomarker Correlated with Immune Infiltrates in Colorectal Cancer: Evidence from Bioinformatic Analysis by Qi Wang, Xufeng Huang, Shujing Zhou, Yuntao Ding, Huizhi Wang, Weiye Jiang, Min Xu

“…The above-mentioned genes might offer a valuable insight into the diagnosis, immunotherapeutic targets, and prognosis of CRC.…”
Get full text

Transplant Tolerance: New Insights and Strategies for Long-Term Allograft Acceptance by Paulina Ruiz, Paula Maldonado, Yessia Hidalgo, Alejandra Gleisner, Daniela Sauma, Cinthia Silva, Juan Jose Saez, Sarah Nuñez, Mario Rosemblatt, Maria Rosa Bono

“…Here, we describe the different treatments and some of the novel immunotherapeutic strategies undertaken to induce transplantation tolerance.…”
Get full text

Peptides as Versatile Regulators in Cancer Immunotherapy: Recent Advances, Challenges, and Future Prospects by Yu Lei, Jiacheng Liu, Yaowei Bai, Chuansheng Zheng, Dongyuan Wang

“…Peptides can act as immunotherapeutic agents for the treatment of many malignant cancers. …”
Get full text

Innate Immune Recognition of Mycobacterium tuberculosis by Johanneke Kleinnijenhuis, Marije Oosting, Leo A. B. Joosten, Mihai G. Netea, Reinout Van Crevel

“…More insight into PRRs and the recognition of mycobacteria, combined with immunogenetic studies in TB patients, does not only lead to a better understanding of the pathogenesis of tuberculosis but also may contribute to the design of novel immunotherapeutic strategies.…”
Get full text

Immunological differences between monophasic and biphasic synovial sarcoma with implications for immunotherapy by S. J. Luk, M. E. IJsselsteijn, A. Somarakis, I. Acem, I. Briaire de Bruijn, K. Szuhai, J. V. M. G. Bovee, N. F. C. C. de Miranda, J. H. F. Falkenburg, M. H. M. Heemskerk

“…Abstract Synovial sarcoma is an aggressive soft-tissue cancer that shows limited responses to current immunotherapeutic approaches using immune checkpoint blockade or adoptive cell therapy. …”
Get full text

TIM‐4 increases the proportion of CD4+CD25+FOXP3+ regulatory T cells in the pancreatic ductal adenocarcinoma microenvironment by inhibiting IL‐6 secretion by Ziyao Wang, Zerong Xie, Yu Mou, Ruiman Geng, Chen Chen, Nengwen Ke

“…Conclusion TIM‐4 has the potential to be an immunotherapeutic target or to improve the efficacy of chemotherapy for PDAC.…”
Get full text

The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook by Hager Mohamed, Vandana Miller, Stephen R. Jennings, Brian Wigdahl, Fred C. Krebs

“…Dendritic cells have thus been recognized as a valuable tool in the development of immunotherapeutic approaches and vaccines effective against HIV-1. …”
Get full text

CDC25B Is a Prognostic Biomarker Associated With Immune Infiltration and Drug Sensitivity in Hepatocellular Carcinoma by Zixiang Huang, Liangzhi Xu, Zhengqiang Wu, Xiaofeng Xiong, Linfei Luo, Zhili Wen

“…CDC25B can be used as a biomarker and immunotherapeutic target for poor prognosis and partial drug sensitivity in HCC, providing new ideas for HCC treatment.…”
Get full text

Modified CD15/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemia by Rui Zhang, Yifan Zhao, Xiao Chai, Yingshuai Wang, Mohan Zhao, Shujing Guo, Yu Zhang, Mingfeng Zhao

“…CLL1 Chimeric antigen receptor T-cell (CAR-T) therapy, as a promising immunotherapeutic approach, has demonstrated its potential to enhance the prognosis of patients diagnosed with acute myeloid leukemia (AML). …”
Get full text

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies by Sahar Balkhi, Giorgia Bilato, Andrea De Lerma Barbaro, Paola Orecchia, Alessandro Poggi, Lorenzo Mortara

“…Innovative IL-2-based immunotherapeutic approaches include immunotoxins, such as antibody–drug conjugates, immunocytokines, and antibody–cytokine fusion proteins that enhance tumor-specific delivery. …”
Get full text

The profiles of immunosuppressive microenvironment in the Lauren intestinal-type gastric adenocarcinoma by Qingyuan Wang, Jia Chen, Yaohui Wang, Xiang Li, Xiaochun Ping, Jiajia Shen, Sheng Yang, Lizong Shen

“…These findings underscore the necessity for targeted strategies that disrupt specific immunosuppressive pathways, potentially enhancing the efficacy of immunotherapeutic interventions in IGAC.…”
Get full text

The Possible Role of TLR2 in Chronic Hepatitis B Patients with Precore Mutation by Malihe Moradzadeh, Sirous Tayebi, Hossein Poustchi, Kourosh Sayehmiri, Parisa Shahnazari, Elnaz Naderi, Ghodratollah Montazeri, Ashraf Mohamadkhani

“…Recognition mechanisms of innate immune response help to improve immunotherapeutic strategies in HBeAg-negative chronic hepatitis B (CHB). …”
Get full text

Dissecting macrophage heterogeneity and kaempferol in lung adenocarcinoma: a single-cell transcriptomic approach and network pharmacology by Laiyi Wan, Wentao Hao, Leilei Li, Lin Wang, Yanzheng Song

“…These findings underscore the translational potential of integrating TCM-derived compounds into immunotherapeutic strategies for LUAD.…”
Get full text

Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives by Dong Luo, Yunmei Liu, Zhengmao Lu, Lei Huang

“…Programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) antibodies are the most commonly used immunotherapeutic agents and have been used with some success in GC treatment. …”
Get full text